Results 101 to 110 of about 21,845 (197)
Despite the proven safety of dystrophin-targeting phosphorodiamidate morpholino oligomer (PMO) therapy, poor delivery of the PMOs limit the efficacy of this dystrophin restoring gene therapy for Duchenne muscular dystrophy (DMD).
Young Jae Moon +6 more
doaj +1 more source
Delandistrogene moxeparvovec is an rAAVrh74 vector-based gene transfer therapy that delivers a transgene encoding delandistrogene moxeparvovec micro-dystrophin, an engineered, functional form of dystrophin shown to stabilize or slow disease progression ...
Rachael A. Potter +14 more
doaj +1 more source
Engineering suppressor tRNAs for effective treatment of Duchenne muscular dystrophy. [PDF]
Oury J +19 more
europepmc +1 more source
Magnetic Mitohormesis as a Potential Non-Invasive Restorative Therapy for X-Linked Muscular Dystrophies. [PDF]
Iversen JN, Franco-Obregón A.
europepmc +1 more source
Four new mouse models of Duchenne muscular dystrophy with clinically relevant exon deletions in the human DMD gene. [PDF]
van Putten M +9 more
europepmc +1 more source
Emerging Roles of Dystroglycan in Cardiac Remodeling, Fibrosis, and Heart Failure. [PDF]
Pradhan BS, Mączewski M.
europepmc +1 more source
Duchenne muscular dystrophy: from gene to gene-ius therapies. [PDF]
Muchir A, Musaro A, Chamberlain J.
europepmc +1 more source
Bridging Duchenne muscular dystrophy therapy from rhesus monkeys to patients. [PDF]
Guo W, Ji W, Chen Y.
europepmc +1 more source
Prime Editing Mediated Generation and Correction of the mdx5cv Mutation Restores Dystrophin Expression in Myoblasts. [PDF]
Siddika A +3 more
europepmc +1 more source

